Tuberculosis and Respiratory Diseases

  • 제61권3호
  • /
  • Pages.285-288
  • /
  • 2006
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

만성활동성C형간염에 대한 인터페론 치료 후 사르코이드증의 악화

Exacerbation of Sarcoidosis Following Interferon-alpha Therapy for Chronic Active Hepatitis C

  • 장혜정 (이화여자대학교 의과대학 내과학교실) ;
  • 최은화 (이화여자대학교 의과대학 내과학교실) ;
  • 김인제 (이화여자대학교 의과대학 내과학교실) ;
  • 심윤수 (이화여자대학교 의과대학 내과학교실) ;
  • 이진화 (이화여자대학교 의과대학 내과학교실) ;
  • 김태헌 (이화여자대학교 의과대학 내과학교실) ;
  • 문진욱 (이화여자대학교 의과대학 내과학교실) ;
  • 천은미 (이화여자대학교 의과대학 내과학교실) ;
  • 김유경 (이화여자대학교 의과대학 방사선과학교실) ;
  • 성순희 (이화여자대학교 의과대학 병리학교실) ;
  • 장중현 (이화여자대학교 의과대학 내과학교실)
  • Chang, Hye Jung (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Choi, Eun Hwa (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Kim, In Je (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Sim, Yun Su (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Lee, Jin Hwa (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Kim, Tae Hun (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Moon, Jin Wook (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Chun, Eun Mi (Department of Internal Medicine, Ewha Women University College of Medicine) ;
  • Kim, Yoo Kyung (Department of Radiology, Ewha Women University College of Medicine) ;
  • Sung, Sun Hee (Department of Pathology, Ewha Women University College of Medicine) ;
  • Chang, Jung Hyun (Department of Internal Medicine, Ewha Women University College of Medicine)
  • 투고 : 2006.05.25
  • 심사 : 2006.07.12
  • 발행 : 2006.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

인터페론 알파는 만성활동성C형간염 환자에서 항바이러스제로 사용되는 면역조절제로, 인터페론 치료가 사르코이드증을 발생시키거나 악화시킬 수 있다고 알려져 있다. 저자 등은 C형간염바이러스 활성화로 인터페론과 ribavirin으로 치료를 받은 후 기존의 폐사르코이드증이 악화되었다가 자연 호전된 예를 경험하였기에 보고하는 바이다.

Interferon alpha is an immunomodulator that is used as an antiviral agent to treat chronic active viral hepatitis C. However, interferon can induce or exacerbate sarcoidosis. We report a case of 42-year-old man with an exacerbation of pulmonary sarcoidosis after the cessation of interferon and ribavirin therapy for chronic hepatitis C. The patient's sarcoidosis improved spontaneously and he continues to be monitored regularly without steroid therapy.

키워드

참고문헌

  1. Sleijfer S, Bannink M, van Gool AR, Kruit WH, Stoter G.Side effects of interferon-alpha therapy. Pharm World Sci 2005:27:423-31 https://doi.org/10.1007/s11096-005-1319-7
  2. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997:26:112S-21S https://doi.org/10.1002/hep.510260720
  3. Blum L, Serfaty L, Wattiaux MJ, Picard O, Cabane J, Imbert JC. Nodules hypodermiques sarcoïdosiques au cours d'une hépatite virale C traitée par interféron alpha 2 b. Rev Med Interne 1993:14(Suppl 462):1161 https://doi.org/10.1016/S0248-8663(05)80273-5
  4. Hoffmann RM, Jung MC, Motz R, Gossl C, Emslander HP, Zachoval R, et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. J Hepatol 1998:28:1058-63 https://doi.org/10.1016/S0168-8278(98)80357-7
  5. Gitlin N. Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases. Eur J Gastroenterol Hepatol 2002:14:883-5 https://doi.org/10.1097/00042737-200208000-00013
  6. Ramos-Casals M, Mana J, Nardi N, Brito-Zeron P, Xaubet A, Sanchez-Tapias JM, et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine 2005:84:69-80 https://doi.org/10.1097/01.md.0000157577.69729.e6
  7. Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O. Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 2003:14:237-43 https://doi.org/10.1016/S0953-6205(03)00078-5
  8. Yoon JG, Ahn JH, Ko SH, Lee HS, Kwon SS, Kim YK, et al. A case of interstitial pneumonitis developed by interferon alpha treatment for chronic hepatitis C. Tuberc Respir Dis 1996:43:637-44 https://doi.org/10.4046/trd.1996.43.4.637
  9. Abdi EA, Nguyen GK, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cell carcinoma. Cancer 1987:59:896-900 https://doi.org/10.1002/1097-0142(19870301)59:5<896::AID-CNCR2820590507>3.0.CO;2-4
  10. Pietropaoli A, Modrak J, Utell M. Interferon-alpha therapy associated with the development of sarcoidosis. Chest 1999:116:569-72 https://doi.org/10.1378/chest.116.2.569
  11. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol 2002:107:133-44 https://doi.org/10.1159/000057631
  12. Parronchi P, Mohapatra S, Sampognaro S, Giannarini L, Wahn U, Chong P, et al. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur J Immunol 1996:26:697-703 https://doi.org/10.1002/eji.1830260328
  13. Baumer I, Zissel G, Schlaak M, Muller-Quernheim J. Th1/Th2 cell distributionin pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1997:16:171-7 https://doi.org/10.1165/ajrcmb.16.2.9032124
  14. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol 1999:30:376-82 https://doi.org/10.1016/S0168-8278(99)80093-2
  15. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci 2004:328:173-5 https://doi.org/10.1097/00000441-200409000-00008